Recent Business Highlights

Proprietary Products: Aspiring to build a $400 million business by FY22 through a low-risk innovation model • Established with the goal to address unmet needs of specific patient segments in Dermatology & Neurology Diverse portfolio of R&D assets with a track record of regulatory success Licensed three clinical stage assets to augment overall long term value of the portfolio Strong track record of commercial success 33% CAGR top-line growth [FY11-FY17] Specialty Dermatology Franchise 3 Products approved; 1 asset commercialized and 2 licensed Supported by 60 Sales Reps in 6 Regions Specialty Neurology Franchise Introduced the Neurology franchise through the launch of Zembrace in 2016 Supported by 45 Sales Reps in 6 Regions • FDA Approval for Five NDAs (organic pipeline assets) Two Launched April/May 2016 ZEMBRACE ™ Sym Touch TM (sumatriptan injection) 3 mg/ 0.5 mL Sernivo™ (betamethasone dipropionate) Spray, 0.05% 22

View entire presentation